Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 6/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30227881 | 1.00 | CACNA1G (0.35) | CACNA1GCACNA1BCACNA1CHTR2CSLC6A4 | |
| SCHEMBL30136111 | 0.90 | CACNA1G (0.37) | CACNA1GCACNA1BCACNA1CHTR2CSLC6A4 | |
| SCHEMBL22012577 | 0.90 | CACNA1G (0.37) | CACNA1GCACNA1BCACNA1CHTR2CSLC6A4 | |
| SCHEMBL21964196 | 0.85 | MAP4K1 (0.33) | MAP4K1 | |
| SCHEMBL22012277 | 0.83 | CACNA1G (0.37) | CACNA1GCACNA1BCACNA1CHTR2CSLC6A4 | |
| SCHEMBL30500363 | 0.83 | CACNA1G (0.37) | CACNA1GCACNA1BCACNA1CHTR2CSLC6A4 | |
| SCHEMBL28975061 | 0.83 | KDM4A (0.35) | CACNA1BCACNA1CMAP4K1 | |
| SCHEMBL22012609 | 0.82 | CACNA1G (0.42) | CACNA1GCACNA1BCACNA1CHTR2CSLC6A4 | |
| SCHEMBL21990476 | 0.81 | CACNA1G (0.38) | CACNA1GCACNA1BCACNA1CHTR2CSLC6A4 | |
| SCHEMBL21990455 | 0.79 | MAP4K1 (0.36) | MAP4K1CYP17A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197703-A1 | Azalactam Compounds as HPK1 Inhibitors | PFIZER INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-3880676-B1 | 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PFIZER (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3880676-B1 | 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PFIZER (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11684616-B2 | Azalactam compounds as HPK1 inhibitors | PFIZER INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11684616-B2 | Azalactam compounds as HPK1 inhibitors | PFIZER INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11684616-B2 | Azalactam compounds as HPK1 inhibitors | PFIZER INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220401424-A1 | Azalactam Compounds as HPK1 Inhibitors | PFIZER INC. (US) | 2022-12-22 | — | — | US | disclosed |
| US-20220401424-A1 | Azalactam Compounds as HPK1 Inhibitors | PFIZER INC. (US) | 2022-12-22 | — | — | US | disclosed |
| WO-2021220185-A1 | AZALACTAM COMPOUNDS AS HPK1 INHIBITORS | PFIZER INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-11142525-B2 | Azalactam compounds as HPK1 inhibitors | PFIZER INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-11142525-B2 | Azalactam compounds as HPK1 inhibitors | PFIZER INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-20200172539-A1 | Azalactam Compounds as HPK1 Inhibitors | PFIZER INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-20200172539-A1 | Azalactam Compounds as HPK1 Inhibitors | PFIZER INC. (US) | 2020-06-04 | — | — | US | disclosed |
| WO-2020100027-A1 | 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PFIZER INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401424-A1 | Azalactam Compounds as HPK1 Inhibitors | CDKN1A, HIPK1, CMPK1 | CACNA1G 4260/4885CACNA1B 4070/4885CACNA1C 4602/4885 |
| US-20200172539-A1 | Azalactam Compounds as HPK1 Inhibitors | CDKN1A, HIPK1, CMPK1 | CACNA1G 4323/4885CACNA1B 4420/4885CACNA1C 4661/4885 |
| US-11142525-B2 | Azalactam compounds as HPK1 inhibitors | CDKN1A, HIPK1, CMPK1 | CACNA1G 4323/4885CACNA1B 4420/4885CACNA1C 4661/4885 |
| US-11684616-B2 | Azalactam compounds as HPK1 inhibitors | CDKN1A, HIPK1, CMPK1 | CACNA1G 4260/4885CACNA1B 4070/4885CACNA1C 4602/4885 |
| US-20240197703-A1 | Azalactam Compounds as HPK1 Inhibitors | CDKN1A, HIPK1, CMPK1 | CACNA1G 4260/4885CACNA1B 4070/4885CACNA1C 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.